The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Pharmacogenetic Testing Market By 2030?
The pharmacogenetic testing market has shown considerable expansion in recent times. It is anticipated to expand from $14.33 billion in 2025 to $16.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.7%. The surge observed in the past period stems from improvements in genomic sequencing technologies, worries regarding adverse drug reactions, an escalating burden of chronic diseases, decreasing genetic testing expenses, and heightened clinical recognition.
The pharmacogenetic testing market is projected to experience significant expansion in the coming years. This market is predicted to reach a value of $29.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.5%. This anticipated growth during the forecast period is driven by several factors, including the advancement of precision healthcare, the wider availability of direct-to-consumer testing, the incorporation with electronic health records, growing regulatory backing, and increased funding in genomics research. Key trends anticipated for the same period encompass the increasing acceptance of personalized medicine, a greater reliance on genetic testing for drug selection, the broadening of applications in oncology and cardiology, a surging need for precision diagnostics, and the incorporation of pharmacogenomics into routine clinical practice.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19139&type=smp
What Influential Factors Are Boosting The Pharmacogenetic Testing Market Demand?
The future expansion of the pharmacogenetic testing market is anticipated, driven by the increasing need for personalized medicine. This healthcare strategy, also known as precision medicine, customizes treatments and medical decisions according to an individual’s specific genetic, biological, and lifestyle characteristics. The demand for personalized medicine is on the rise because it enhances treatment outcomes, supports timely disease detection, and improves cost-effectiveness in patient care. The pharmacogenetic testing market plays a crucial role in personalized medicine by analyzing a person’s genetic profile to predict drug responses, thereby enabling optimal treatment selection and reducing the likelihood of adverse reactions. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based non-profit organization, indicated that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, a considerable increase from 6 approvals in 2022. Thus, the escalating demand for personalized medicine is propelling the growth of the pharmacogenetic testing market.
What Key Segment Areas Are Included In The Pharmacogenetic Testing Market Assessment?
The pharmacogenetic testing market covered in this report is segmented –
1) By Type: Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, Single Gene Tests
2) By Drug Type: Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, Over-The-Counter Medications
3) By Therapeutic Area: Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology And Hypersensitivity, Dermatology, Gynecology, Oncology, Other Therapeutic Areas
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services
5) By End User: Healthcare Providers, Pharmaceutical And Biotechnology Companies, Centers And Academic Institutes, Other End Users
Subsegments:
1) By Whole Genome Sequencing: Illumina Sequencing, Ion Torrent Sequencing, Pacific Biosciences Sequencing, Oxford Nanopore Sequencing
2) By Whole Exome Sequencing: Capture-Based Exome Sequencing, Targeted Enrichment Exome Sequencing, Hybridization-Based Exome Sequencing
3) By Array-Based Tests: SNP Array Testing, Expression Array Testing, Copy Number Variation Array Testing
4) By Single Gene Tests: Targeted Gene Panels, Mutation Detection Tests, Sequencing Of Specific Genes
Which Trends Are Influencing The Expansion Of The Pharmacogenetic Testing Market?
Key companies operating within the pharmacogenetics testing market are concentrating on the development of advanced pharmacogenomics testing services, including prescription-based pharmacogenetic testing, with the aim of boosting medication safety, increasing treatment accuracy, and supporting personalized therapeutic choices. Prescription-based pharmacogenetic testing involves genetic analyses initiated by licensed healthcare providers to assess how an individual’s genetic composition affects their response to particular medications, thereby allowing clinicians to refine drug selection and dosing while mitigating the probability of adverse drug reactions. For example, in May 2023, UCSF, a US-based healthcare organization, introduced its pharmacogenomics testing service designed to enhance the precision of medical treatments, furnishing healthcare professionals with genetic data that assists in tailoring drug therapies to each patient’s distinct profile, thereby strengthening drug efficacy and reducing the potential for harmful side effects.
Who Are The Firms Contributing To The Pharmacogenetic Testing Market Ecosystem?
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC
Access The Complete Pharmacogenetic Testing Market Report:
https://www.thebusinessresearchcompany.com/report/pharmacogenetic-testing-global-market-report
Which Region Contributes The Most To The Pharmacogenetic Testing Market?
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Pharmacogenetic Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=19139&type=smp
Browse Through More Reports Similar to the Global Pharmacogenetic Testing Market 2026, By The Business Research Company
Neurogenetic Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report
Genetic Toxicology Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/genetic-toxicology-testing-global-market-report
Genetic Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model